Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2025
Date Filed: July 14, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document does not contain a financial statement or specific numerical metrics for the period.
Material Changes
The filing does not disclose material changes in financial position or operations compared to a prior comparable period. The primary content is the submission of a response to an ASX Price Query.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a "Response to ASX Price Query" as Exhibit 99.1. The text of the response is not included in the provided content.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: The filing is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Investor Verification Checklist
- Review the full text of Exhibit 99.1 ("Response to ASX Price Query") to understand the specific market query addressed.
- Verify the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential capital raising activities.
- Confirm the company's current cash runway and burn rate, as no financial data is present in this specific filing.
- Monitor subsequent filings for updates on the development stage pipeline, given the lack of operational metrics here.